Cargando…
Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
The most efficacious antimicrobial therapy to aid in the successful elimination of resistant S. aureus infections is unknown. In this study, we evaluated varying phenotypes of S. aureus against dalbavancin (DAL), vancomycin (VAN), and daptomycin (DAP) alone and in combination with cefazolin (CFZ). T...
Autores principales: | Abdul-Mutakabbir, Jacinda C., Kebriaei, Razieh, Stamper, Kyle C., Sheikh, Zain, Maassen, Philip T., Lev, Katherine L., Rybak, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602181/ https://www.ncbi.nlm.nih.gov/pubmed/33066415 http://dx.doi.org/10.3390/antibiotics9100696 |
Ejemplares similares
-
1539. Dalbavancin, Vancomycin, and Daptomycin Alone and in Combination with Cefazolin Against Vancomycin Intermediate-Resistant (VISA) and Daptomycin Non-Susceptible (DNS) Staphylococcus aureus
por: Abdul-Mutakabbir, Jacinda, et al.
Publicado: (2019) -
Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin
por: Kebriaei, Razieh, et al.
Publicado: (2023) -
Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of Staphylococcus aureus
por: Kebriaei, Razieh, et al.
Publicado: (2017) -
2391. Liposomal Vancomycin and Cefazolin Combinations for S. aureus Biofilms
por: Kebriaei, Razieh, et al.
Publicado: (2018) -
The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy
por: Morrisette, Taylor, et al.
Publicado: (2020)